Close Menu
Control.vg
  • Home
  • News
  • Politics
  • Finance
  • Business
  • Markets
  • Games
    • Mobile
    • PlayStation
    • Xbox
  • Technology
  • Entertainment
  • Sports

Subscribe to Updates

Get the latest news and updates directly to your inbox.

What's Hot

Pentagon L3Harris Investment Signals a New Era for America’s Missile Supply Chain

The Hidden Cost of High Rates – Why the Small Business Boom is Suddenly Busting

The Great Corporate Tax Dodge of 2026 – How Multinationals Are Shielding Profits

Facebook X (Twitter) Instagram
RSS
Control.vg
Subscribe Now
  • Home
  • News
  • Politics
  • Finance
  • Business
  • Markets
  • Games
    • Mobile
    • PlayStation
    • Xbox
  • Technology
  • Entertainment
  • Sports
Control.vg
You are at:Home » Monteris Medical secures 28 million dollars in Series E funding for robotic neurosurgery technology
Technology

Monteris Medical secures 28 million dollars in Series E funding for robotic neurosurgery technology

By Marcus ThorneMarch 13, 20263 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Email

Monteris Medical has successfully closed a $28 million Series E equity financing round to support the continued advancement of its robotic minimally invasive neurosurgery technology. The Minnetonka, Minnesota-based company also announced that it has refinanced its existing debt and established a new $35 million credit facility with Trinity Capital. The combined funding will enable Monteris to expand its commercial presence and accelerate research and development initiatives for its NeuroBlate system.

According to the company, the equity capital will specifically support research and development efforts along with other growth initiatives. Meanwhile, the credit facility will back expansion of the company’s U.S. commercial footprint and fuel additional strategic growth programs.

Monteris Medical NeuroBlate System Technology

Monteris commercialized its NeuroBlate system in 2013, and the technology has since been used in more than 9,000 clinical cases across nearly 130 health systems throughout North America. The system delivers MRI-guided laser ablation for laser interstitial thermal therapy, commonly known as LITT, which represents a minimally invasive treatment option for complex neurological diseases.

The robotically-controlled NeuroBlate system utilizes laser energy to destroy abnormal brain tissue through a small hole in the skull. This approach treats conditions including primary and metastatic brain tumors, radiation necrosis, and epileptogenic foci. According to Monteris, the NeuroBlate system is the only FDA-approved LITT system featuring a robotic platform.

LITT technology offers patients an alternative to traditional open-skull craniotomy procedures for abnormal brain tissue ablation. This minimally invasive approach can potentially reduce recovery times and complications associated with more invasive surgical techniques.

Investor Participation and Strategic Partnerships

The Series E financing round included participation from Monteris Medical’s current lead investors, InnovaHealth Partners and Birchview Capital. Additionally, several new investors joined the round, including OSF Ventures, the investment arm of Peoria, Illinois-based OSF HealthCare, and the Colorado University Healthcare Innovation Fund.

Notably, the healthcare system venture funds participating in the round are affiliated with institutions that already offer NeuroBlate technology to their patients. Madryn Asset Management, the company’s previous credit facility partner, also participated as a major investor in the equity round.

Mayank Taneja, VP of Venture Investments at OSF Ventures, stated in a news release that the organization seeks to invest in companies bringing meaningful innovation to clinicians and patients. He noted that OSF clinicians have firsthand experience using Monteris’ technology in practice, and their vision of improving patient lives aligns with Monteris’ mission to deliver hope and healing.

Growing Clinical Demand for Minimally Invasive Neurosurgery

The investment comes as Monteris continues building momentum in the minimally invasive neurosurgery market. Richard Emmitt, Monteris’ board chair, indicated that the company is becoming the preferred partner for neurosurgeons seeking minimally invasive options for patients with brain tumors and drug-resistant epilepsy. He emphasized that support from both new and existing investors reflects strong confidence in the NeuroBlate technology and growing clinical demand.

Furthermore, Monteris recently achieved a significant reimbursement milestone by securing LITT coverage for more than 9 million military members, veterans, and their families enrolled in Tricare. This coverage expansion enhances access to the minimally invasive neurosurgery technology for a substantial patient population.

As part of the financing round, Mayank Taneja and Alex Marcantonio, managing director of Madryn Asset Management, have been added to Monteris Medical’s board of directors. The company has not disclosed specific timelines for its planned commercial expansion or research and development initiatives funded by the new capital.

Author

  • Marcus Thorne
    Marcus Thorne
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleMoore Regional Hospital Ranks Among Top 10 in State
Next Article Four killed in US refueling plane crash as Trump issues new Iran threat

Related Articles

Apple’s Vision Pro Sold Half the Units Analysts Expected – Tim Cook’s Boldest Bet Is Wobbling.

April 27, 2026

How a Tiny Comet Near the Sun Is Teaching Scientists Everything They Were Wrong About Spin Physics

April 23, 2026

Meet the Artemis II Rescue Crew – NASA’s Emergency Protocols for the Lunar Launch

April 23, 2026

The Best Laptop for Trading Crypto in 2026 – A High-Stakes Hardware Guide

April 20, 2026

Microsoft Stock Reaction Publicis Deal – Why Investors Shrugged at One of the Biggest AI Marketing Partnerships in Years

April 17, 2026

The Fed’s AI Blind Spot – How Algorithmic Trading is Masking True Inflation

April 17, 2026

Top Articles

The Hidden Cost of High Rates – Why the Small Business Boom is Suddenly Busting

April 30, 2026

The Great Corporate Tax Dodge of 2026 – How Multinationals Are Shielding Profits

April 29, 2026

Oil at $120 Is Goldman Sachs’s Worst-Case Scenario – Markets Are Already Halfway There.

April 29, 2026

Latest Articles

The Retail Apocalypse 2.0 – Mid-Market Brands Squeezed Between Luxury and Discount

By adminApril 29, 2026

The Regulatory Rollback – Wall Street Prepares for a Golden Era of Megabank Mergers

By adminApril 29, 2026

Duke Energy CEO Compensation $13.6M Lands the Same Week the Company Begs for a Rate Hike

By adminApril 29, 2026
Most Popular

Stock Split Explained, Why Companies Cut Their Share Price — and What It Really Means for You

April 15, 2026

How a Single Short-Seller Report Erased $1 Billion from the UK Car Finance Market

March 19, 2026

The Wow! Signal Decoded? Astronomers Uncover a Disturbing Pattern in Fast Radio Bursts

March 19, 2026
Pages
  • Contact
  • Homepage
  • Privacy Policy
  • Terms of use
Contact

Control LLC trading as control.vg

Keyway Chambers
Quastisky Building
Road Town, Tortola
British Virgin Islands

contact@control.vg

© 2026 Control LLC trading as Control.vg. ⚠ Investment Disclaimer Investment Warning: All information provided on Primary Ignition is for educational and informational purposes only. Stock markets involve substantial risk of loss and are not suitable for every investor. Past performance is not indicative of future results. Always conduct your own research and consult with licensed financial advisors before making investment decisions. We do not provide investment advice, and no content should be considered as such.

Type above and press Enter to search. Press Esc to cancel.